In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes

Pharmacology Biochemistry and Behavior

Volumn 102, Issue 2, 2012, Pages 312-320

  Schmitt, Ulrich ^a   Kirschbaum, Katrin M ^a   Poller, Birk ^b   Kusch Poddar, Manisha ^b   Drewe, Jürgen ^b   Hiemke, Christoph ^a   Gutmann, Heike ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antipsychotics; Blood brain barrier; Mice; P glycoprotein; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLYCOPROTEIN P; NORCLOZAPINE; OLANZAPINE; QUETIAPINE; RHODAMINE 123;

ANIMAL CELL; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG DISPOSITION; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; DOPAMINE ANTAGONISTS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PROTEIN TRANSPORT; RECEPTORS, DOPAMINE D2; RHODAMINE 123; ROTAROD PERFORMANCE TEST;

MUS;

EID: 84861674275     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.04.002     Document Type: Article

References (38)

1. Abou El Ela A, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds -implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004;56:967-75.
2. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002;71:163-9.
3. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008;42:89-97.
4. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004;64:3296-301.
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
6. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990;10: 1652-63.
7. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 2005;33:165-74.
8. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69.
9. Härtter S, Hüwel S, Lohmann T, Abou El Ela A, Langguth P, Hiemke C, Galla HJ. How does the benzamide antipsychotic amisulpride get into the brain?-an in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 2003; 28:1916-22.
10. Henning U, Loffler S, Krieger K, Klimke A. Uptake of clozapine into HL-60 promyelocytic leukaemia cells. Pharmacopsychiatry 2002;35:90-5.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
12. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29: 319-26.
13. Kirschbaum KM, Hiemke C, Schmitt U. RotaRod impairment: catalepsy-like screening test for antipsychotic side effects. Int J Neurosci 2009:1191509-22.
14. Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008;188:298-303.
15. Lane HY, Jann MW, Chang YC, Chiu CC, Huang MC, Lee SH, et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001;62:812-7.
16. Lin YC, Ellingrod VL, Bishop JR, Miller del D. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 2006;28:668-72.
17. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of Pglycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005;49:610-7.
18. Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang JS, Zhu HJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006;46:164-71.
19. Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007;41:673-9.
20. Nakagami T, Yasui-Furukori N, Saito M, Teteishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005;78: 43-51.
21. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S. Amisulpride the 'atypical'atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008;105:224-35.
22. Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, Mathé AA, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2011;25:896-907.
23. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280:73-82.
24. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56:683-90.
25. Rahi M, Heikkinen T, Härtter S, Hakkola J, Hakala K, Wallerman O, et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 2007;21: 751-6.
26. Sachse J, Härtter S, Weigmann H, Hiemke C. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J Chromatogr B 2003;784:405-10.
27. Sachse J, Köller J, Härtter S, Hiemke C. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B 2006; 830:342-8.
28. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
29. Schmitt U, Abou El-Ela A, Guo LJ, Glavinas H, Krajcsi P, Baron JM, Tillmann C, Hiemke C, Langguth P, Hartter S. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm 2006;113:787-801.
30. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280: 83-97.
31. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of Pglycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
32. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
33. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003a;37:179-85.
34. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003b;54:840-6.
35. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000;22:380-7.
36. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004a;7:415-9.
37. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 2004b;29:551-7.
38. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006;187:415-23.